Clinical trials: Dry Macular Degeneration
Drusen Stage Macular Degeneration
Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography
The objective of this study is to compare the areas designated as elevated retinal pigment epithelium (RPE) by the Cirrus HD-OCT versus those designated as drusen on color fundus photographs (CFPs).
- Trial name
- NCT01272063
- Where
- 4 sites in United States
- Volunteers
- 91 people
- Sponsor
- Carl Zeiss Meditec, Inc.
Nonexudative Age-related Macular Degeneration
Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration
The purpose of this study is to evaluate clinical outcomes of Photobiomodulation treatment on patients with dry Age Related Macular Degeneration (AMD).
- Trial name
- TORPA (NCT00940407)
- Testing
- Photobiomodulation (Gentlewaves, Warp 10)
- Where
- 2 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Merry, Graham, M.D.
Epiretinal Membrane, Dry Age Related Macular Degeneration
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
- Conditions
- Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
- Trial name
- NCT07680244
- Testing
- PathFinder 1.0 on CIRRUS HD-OCT
- Where
- 6 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec-Dublin CoCe
Age Related Macular Degeneration (AMD)
Production of iPSC Derived RPE Cells for Transplantation in AMD
No treatments exist for Age-related Macular Degeneration (AMD) when there is cell loss such as in late wet AMD or dry AMD. The differentiation of RPE cells from patient derived iPSC will offer valuable source of tissue for…
- Trial name
- NCT02464956
- Volunteers
- 3 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Dry Age-related Macular Degeneration
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
- Trial name
- NCT07770828
- Testing
- OCU410
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Ocugen
Age-related Macular Degeneration
Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy
The purpose of this study is to define phenotypic variations in atrophic Age-Related Macular Degeneration (AMD) and to identify predictive factors for disease progression based on fundus autofluorescence imaging.
- Trial name
- NCT00393692
- Where
- 7 sites in Germany
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Geographic Atrophy
A Study in Adults With Geographic Atrophy
The purpose of this clinical research study is to look at how safe STL303 is and whether it works when given to people with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
- Trial name
- NCT07606365
- Testing
- STL303
- Where
- 56 sites in United States, Argentina and 5 more
- Volunteers
- 300 people
- Sponsor
- Sitala Bio LTD
Dry AMD, Overactive Bladder
Mirabegron in Patients With Age-Related Macular Degeneration
The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder.
- Trial name
- NCT07305298
- Testing
- Mirabegron 50mg, Solifenacin 5mg
- Where
- Italy
- Volunteers
- 312 people
- Sponsor
- University of Naples
Age Related Macular Degeneration
Carbidopa-Levodopa in Dry AMD With Geographic Atrophy
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
- Trial name
- NCT03451500
- Testing
- carbidopa-levodopa
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Age-Related Macular Degeneration
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A fellow eye controlled study of HUCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD. All subjects will be assigned to HUCNS-SC transplantation.
- Trial name
- RADIANT (NCT02467634)
- Testing
- HuCNS-SC sub-retinal transplantation
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- StemCells, Inc.
Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Trial name
- NCT07851259
- Testing
- RO7965032
- Where
- 5 sites in United States
- Volunteers
- 321 people
- Sponsor
- Genentech, Inc.
Dry Age-related Macular Degeneration, Geographic Atrophy
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04643886
- Testing
- GEM103
- Where
- 29 sites in United States
- Volunteers
- 62 people
- Sponsor
- Gemini Therapeutics, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Geographic Atrophy, Age-Related Macular Degeneration
Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
The purpose of this study is to characterize emixustat hydrochloride pharmacokinetic and pharmacodynamic parameters in subjects with geographic atrophy associated with dry age-related macular degeneration.
- Trial name
- NCT02130531
- Testing
- Emixustat HCl Tablet
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Kubota Vision Inc.
Geographic Atrophy, Macular Degeneration
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
- Trial name
- NCT04435366
- Testing
- Avacincaptad Pegol
- Where
- 205 sites in United States, Argentina and 18 more
- Volunteers
- 448 people
- Sponsor
- IVERIC bio, Inc.
Age-related Macular Degeneration
Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).
- Trial name
- NCT01835015
- Testing
- CLG561
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Atrophy, Geographic
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles…
- Trial name
- NCT02033668
- Testing
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neovascular Age-related Macular Degeneration
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the…
- Trial name
- TALON Ext (NCT04597632)
- Testing
- brolucizumab
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age Related Macular Degeneration
Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a…
- Trial name
- NCT00541333
- Testing
- Copaxone Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The New York Eye & Ear Infirmary
Macular Degeneration, Macular Degeneration, Wet
Prediction of Progression of Age-Related Macular Degeneration
The goal for this study is to initiate a randomized, controlled clinical trial to test the viability of personalized AMD progression prediction models.
- Conditions
- Macular Degeneration, Macular Degeneration, Wet, Macular Degeneration, Dry
- Trial name
- NCT04640649
- Testing
- Algorithm prediction
- Volunteers
- 278 people
- Sponsor
- University of Illinois Chicago